PROMACTA Patient Email
This email is designed to introduce patients to PROMACTA, a treatment for immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). More specifically, it is meant to position PROMACTA as a superior alternative to steroids and motivate patients to make the switch.
Year
2024
Client
Novartis
KYMRIAH Data Leave-behind
This asset synthesizes data from KYMRIAH clinical and real-world trials. The ELARA trial—the pivotal trial in r/r FL—provided controlled clinical data, while the Center for International Blood and Marrow Transplant Research Cellular Therapy Registry (CIBMTR-CTR) provided real-world insights.
As the lead writer on this project, I interpreted clinical and real-world data and shaped them into, clear, approvable, on-strategy copy.
View full piece here.
Client
Novartis
Year
2024
Mechanism of Action Video
In June of this year, the first-and-only PROTAC estrogen receptor degrader for ER+/HER2– metastatic breast cancer is set to launch.
Although PROTAC (PROteolysis-TArgeting Chimera) technology represents a breakthrough in the treatment of this condition, many HCPs struggle to differentiate it from SERDs. This video introduces this treatment as a new standard of care, and explains what sets it apart from other breast cancer therapies.
As the lead writer on this project, I wrote the script, collaborated closely with art to create the storyboard, and worked with a team of developers to bring the video to life.
Because this product is yet to launch, I cannot include the entire video in the portfolio.
Client
Pfizer/ARVINAS
Year
2025
Other Notable Work
One of the brands I’m working on is pre-launch and therefore cannot be included in this portfolio.
For this therapy, I wrote the MOA video (previewed above), an objection handler, and a journal ad. The MOA story is a core pillar of the brand, and language from that work has since been carried into several other pieces.
I have also contributed copy across additional brand assets, including the CVA, IVA, HCP brochure, and HCP website.